510 related articles for article (PubMed ID: 18276844)
1. IL-2 and IL-21 confer opposing differentiation programs to CD8+ T cells for adoptive immunotherapy.
Hinrichs CS; Spolski R; Paulos CM; Gattinoni L; Kerstann KW; Palmer DC; Klebanoff CA; Rosenberg SA; Leonard WJ; Restifo NP
Blood; 2008 Jun; 111(11):5326-33. PubMed ID: 18276844
[TBL] [Abstract][Full Text] [Related]
2. Active STAT5 regulates T-bet and eomesodermin expression in CD8 T cells and imprints a T-bet-dependent Tc1 program with repressed IL-6/TGF-β1 signaling.
Grange M; Verdeil G; Arnoux F; Griffon A; Spicuglia S; Maurizio J; Buferne M; Schmitt-Verhulst AM; Auphan-Anezin N
J Immunol; 2013 Oct; 191(7):3712-24. PubMed ID: 24006458
[TBL] [Abstract][Full Text] [Related]
3. Interleukin-2 and inflammation induce distinct transcriptional programs that promote the differentiation of effector cytolytic T cells.
Pipkin ME; Sacks JA; Cruz-Guilloty F; Lichtenheld MG; Bevan MJ; Rao A
Immunity; 2010 Jan; 32(1):79-90. PubMed ID: 20096607
[TBL] [Abstract][Full Text] [Related]
4. A Context-Dependent Role for IL-21 in Modulating the Differentiation, Distribution, and Abundance of Effector and Memory CD8 T Cell Subsets.
Tian Y; Cox MA; Kahan SM; Ingram JT; Bakshi RK; Zajac AJ
J Immunol; 2016 Mar; 196(5):2153-66. PubMed ID: 26826252
[TBL] [Abstract][Full Text] [Related]
5. Interleukin-21 induces the differentiation of human Tc22 cells via phosphorylation of signal transducers and activators of transcription.
Liu Y; Yang B; Ma J; Wang H; Huang F; Zhang J; Chen H; Wu C
Immunology; 2011 Apr; 132(4):540-8. PubMed ID: 21214545
[TBL] [Abstract][Full Text] [Related]
6. A Th17-like developmental process leads to CD8(+) Tc17 cells with reduced cytotoxic activity.
Huber M; Heink S; Grothe H; Guralnik A; Reinhard K; Elflein K; Hünig T; Mittrücker HW; Brüstle A; Kamradt T; Lohoff M
Eur J Immunol; 2009 Jul; 39(7):1716-25. PubMed ID: 19544308
[TBL] [Abstract][Full Text] [Related]
7. Lactate dehydrogenase inhibition synergizes with IL-21 to promote CD8
Hermans D; Gautam S; García-Cañaveras JC; Gromer D; Mitra S; Spolski R; Li P; Christensen S; Nguyen R; Lin JX; Oh J; Du N; Veenbergen S; Fioravanti J; Ebina-Shibuya R; Bleck C; Neckers LM; Rabinowitz JD; Gattinoni L; Leonard WJ
Proc Natl Acad Sci U S A; 2020 Mar; 117(11):6047-6055. PubMed ID: 32123114
[TBL] [Abstract][Full Text] [Related]
8. Prolonged interleukin-2Ralpha expression on virus-specific CD8+ T cells favors terminal-effector differentiation in vivo.
Kalia V; Sarkar S; Subramaniam S; Haining WN; Smith KA; Ahmed R
Immunity; 2010 Jan; 32(1):91-103. PubMed ID: 20096608
[TBL] [Abstract][Full Text] [Related]
9. Type 17 CD8+ T cells display enhanced antitumor immunity.
Hinrichs CS; Kaiser A; Paulos CM; Cassard L; Sanchez-Perez L; Heemskerk B; Wrzesinski C; Borman ZA; Muranski P; Restifo NP
Blood; 2009 Jul; 114(3):596-9. PubMed ID: 19471017
[TBL] [Abstract][Full Text] [Related]
10. CD8
Mellouk A; Bobé P
FASEB J; 2019 Mar; 33(3):3225-3236. PubMed ID: 30383448
[TBL] [Abstract][Full Text] [Related]
11. Distinct roles for IL-2 and IL-15 in the differentiation and survival of CD8+ effector and memory T cells.
Mitchell DM; Ravkov EV; Williams MA
J Immunol; 2010 Jun; 184(12):6719-30. PubMed ID: 20483725
[TBL] [Abstract][Full Text] [Related]
12. Usefulness of IL-21, IL-7, and IL-15 conditioned media for expansion of antigen-specific CD8+ T cells from healthy donor-PBMCs suitable for immunotherapy.
Chamucero-Millares JA; Bernal-Estévez DA; Parra-López CA
Cell Immunol; 2021 Feb; 360():104257. PubMed ID: 33387685
[TBL] [Abstract][Full Text] [Related]
13. Induction of granzyme B and T cell cytotoxic capacity by IL-2 or IL-15 without antigens: multiclonal responses that are extremely lytic if triggered and short-lived after cytokine withdrawal.
Tamang DL; Redelman D; Alves BN; Vollger L; Bethley C; Hudig D
Cytokine; 2006 Nov; 36(3-4):148-59. PubMed ID: 17188506
[TBL] [Abstract][Full Text] [Related]
14. Functional heterogeneity of human effector CD8+ T cells.
Takata H; Naruto T; Takiguchi M
Blood; 2012 Feb; 119(6):1390-8. PubMed ID: 22174157
[TBL] [Abstract][Full Text] [Related]
15. Priming of naive CD8+ T cells in the presence of IL-12 selectively enhances the survival of CD8+CD62Lhi cells and results in superior anti-tumor activity in a tolerogenic murine model.
Díaz-Montero CM; El Naggar S; Al Khami A; El Naggar R; Montero AJ; Cole DJ; Salem ML
Cancer Immunol Immunother; 2008 Apr; 57(4):563-72. PubMed ID: 17726606
[TBL] [Abstract][Full Text] [Related]
16. Human effector T cells derived from central memory cells rather than CD8(+)T cells modified by tumor-specific TCR gene transfer possess superior traits for adoptive immunotherapy.
Wu F; Zhang W; Shao H; Bo H; Shen H; Li J; Liu Y; Wang T; Ma W; Huang S
Cancer Lett; 2013 Oct; 339(2):195-207. PubMed ID: 23791878
[TBL] [Abstract][Full Text] [Related]
17. Differentiation of CD8+ T cells from tumor-invaded and tumor-free lymph nodes of melanoma patients: role of common gamma-chain cytokines.
Anichini A; Scarito A; Molla A; Parmiani G; Mortarini R
J Immunol; 2003 Aug; 171(4):2134-41. PubMed ID: 12902520
[TBL] [Abstract][Full Text] [Related]
18. Brain microenvironment promotes the final functional maturation of tumor-specific effector CD8+ T cells.
Masson F; Calzascia T; Di Berardino-Besson W; de Tribolet N; Dietrich PY; Walker PR
J Immunol; 2007 Jul; 179(2):845-53. PubMed ID: 17617575
[TBL] [Abstract][Full Text] [Related]
19. Eomesodermin Increases Survival and IL-2 Responsiveness of Tumor-specific CD8+ T Cells in an Adoptive Transfer Model of Cancer Immunotherapy.
Furusawa A; Reiser J; Sadashivaiah K; Simpson H; Banerjee A
J Immunother; 2018; 41(2):53-63. PubMed ID: 29271784
[TBL] [Abstract][Full Text] [Related]
20. IL-21 promotes differentiation of naive CD8 T cells to a unique effector phenotype.
Casey KA; Mescher MF
J Immunol; 2007 Jun; 178(12):7640-8. PubMed ID: 17548600
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
